BJDX News & Events

NorthStrive Fund II issued an open letter to the Board of Directors and shareholders of Bluejay Diagnostics, recommending the Board evaluate a strategic opportunity that NorthStrive believes could significantly enhance long-term shareholder value. The company said, "NorthStrive Fund is a significant shareholder of Bluejay and previously disclosed its ownership in a Schedule 13G filed with the U.S. Securities and Exchange Commission on February 5, 2026. In the letter, NorthStrive Fund expressed support for the Board and management team's continued progress advancing the Company's current core program, SYMON II, while encouraging the Company to strengthen its strategic positioning through pipeline expansion capable of introducing additional clinical milestones and value-inflection points. The letter recommends that the Board review the potential acquisition of a Phase-1-ready therapeutic asset targeting refractory chronic cough, a condition affecting millions of patients globally and representing a market opportunity estimated to exceed $10 billion annually. According to NorthStrive Fund, adding a differentiated clinical-stage program could diversify development risk, increase investor visibility, and introduce multiple clinical catalysts that support stronger long-term market valuation. The proposal also notes that financing has been arranged for the potential acquisition through a public-company financing structure, which could support advancement of the program while strengthening the Company's capital position. NorthStrive Fund believes the addition of a differentiated, capital-efficient clinical program capable of delivering near-term milestones could materially strengthen the Company's pipeline and create meaningful upside for shareholders."

Bluejay continues to advance its Symphony platform, including the company's lead product candidate for the rapid measurement of Interleukin-6 to support sepsis risk assessment and critical-care decision making. The company confirmed that its SYMON II clinical study is progressing as planned, with ongoing site activities and enrollment consistent with internal timelines. Data generated from this study is intended to support the company's regulatory strategy. Due to regulatory considerations, including FDA requirements and disclosure constraints, Bluejay may be limited in its ability to release detailed clinical data prior to regulatory submission; however, the company intends to provide appropriate updates in accordance with the analysis of primary end points with the study's statistical analysis plan.

Bluejay Diagnostics announced that it has successfully enrolled 545 patients in its SYMON II multicenter clinical study and has made substantial progress in advancing manufacturing readiness and technology transfer initiatives into 2026, representing a key execution milestone as the company transitions from clinical enrollment toward data analysis, regulatory engagement, and commercialization readiness.

Bluejay Diagnostics Inc trading halted, news pending